and epitope-optimized antibody–drug conjugates, to bispecific antibodies and chimeric antigen receptors for cell-based therapies. RubrYc’s collaboration model includes options for co-discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback